Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Lucintel | PRODUCT CODE: 1386284

Cover Image

PUBLISHER: Lucintel | PRODUCT CODE: 1386284

Human Papillomavirus (HPV) Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2030

PUBLISHED:
PAGES: 150 Pages
DELIVERY TIME: 3 business days
SELECT AN OPTION
PDF (Single User License)
USD 4850
PDF (2 Users License)
USD 5800
PDF (5 Users License)
USD 6700
PDF (Corporate License)
USD 8850

Add to Cart

Human Papillomavirus (HPV) Vaccine Trends and Forecast

The future of the global human papillomavirus (HPV) vaccine market looks promising with opportunities in the hospital & retail pharmacy and government supplier channels. The global human papillomavirus (HPV) vaccine market is expected to reach an estimated $10.3 billion by 2030 with a CAGR of 10.4% from 2024 to 2030. The major drivers for this market are increasing awareness of the benefits of HPV vaccination, rising prevalence of HPV infection, and rising government initiatives to promote HPV vaccination.

A more than 150-page report is developed to help in your business decisions.

Human Papillomavirus (HPV) Vaccine by Segment

The study includes a forecast for the global human papillomavirus (HPV) vaccine by type, distribution channel, and region.

Human Papillomavirus (HPV) Vaccine Market by Type [Shipment Analysis by Value from 2018 to 2030]:

  • Tetravalent
  • Nonavalent
  • Bivalent

Human Papillomavirus (HPV) Vaccine Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:

  • Hospital & Retail Pharmacies
  • Government Suppliers
  • Others

Human Papillomavirus (HPV) Vaccine Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Human Papillomavirus (HPV) Vaccine Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies human papillomavirus (HPV) vaccine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the human papillomavirus (HPV) vaccine companies profiled in this report include-

  • Johnson & Johnson
  • Xenetic Biosciences
  • AstraZeneca
  • Merck
  • Serum Institute Of India
  • Inovio Pharmaceuticals
  • Bharat Biotech
  • Sanofi
  • GlaxoSmithKline
  • Novartis

Human Papillomavirus (HPV) Vaccine Market Insights

Lucintel forecasts that tetravalent is expected to witness highest growth over the forecast period due to its significant usage among girls and boys ages 9 through 12 owing to its features like safety and effectiveness.

North America is expected to witness highest growth over the forecast perioddue to higher adopotion of HPV vaccine and increasing government initiatives to promote HPV vaccination in the region.

Features of the Global Human Papillomavirus (HPV) Vaccine Market

Market Size Estimates: Human papillomavirus (HPV) vaccine market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Human papillomavirus (HPV) vaccine market size by type, distribution channel, and region in terms of value ($B).

Regional Analysis: Human papillomavirus (HPV) vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, distribution channels, and regions for the human papillomavirus (HPV) vaccine market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the human papillomavirus (HPV) vaccine market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1 What is the human papillomavirus (HPV) vaccine market size?

Answer: The global human papillomavirus (HPV) vaccine market is expected to reach an estimated $10.3 billion by 2030.

Q.2 What is the growth forecast for human papillomavirus (HPV) vaccine market?

Answer: The global human papillomavirus (HPV) vaccine market is expected to grow with a CAGR of 10.4% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the human papillomavirus (HPV) vaccine market?

Answer: The major drivers for this market are increasing awareness of the benefits of HPV vaccination, rising prevalence of HPV infection, and rising government initiatives to promote HPV vaccination.

Q4. What are the major segments for human papillomavirus (HPV) vaccine market?

Answer: The future of the human papillomavirus (HPV) vaccine market looks promising with opportunities in the hospital & retail pharmacy and government supplier channels.

Q5. Who are the key human papillomavirus (HPV) vaccine market companies?

Answer: Some of the key human papillomavirus (HPV) vaccine companies are as follows:

  • Johnson & Johnson
  • Xenetic Biosciences
  • AstraZeneca
  • Merck
  • Serum Institute Of India
  • Inovio Pharmaceuticals
  • Bharat Biotech
  • Sanofi
  • GlaxoSmithKline
  • Novartis

Q6. Which human papillomavirus (HPV) vaccine market segment will be the largest in future?

Answer: Lucintel forecasts that tetravalent is expected to witness highest growth over the forecast period due to its significant usage among girls and boys ages 9 through 12 owing to its features like safety and effectiveness.

Q7. In human papillomavirus (HPV) vaccine market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness highest growth over the forecast perioddue to higher adopotion of HPV vaccine and increasing government initiatives to promote HPV vaccination in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the human papillomavirus (HPV) vaccine market by type (tetravalent, nonavalent, and bivalent), distribution channel (hospital & retail pharmacies, government suppliers, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Human Papillomavirus (HPV) Vaccine Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Human Papillomavirus (HPV) Vaccine Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Human Papillomavirus (HPV) Vaccine Market by Type
    • 3.3.1: Tetravalent
    • 3.3.2: Nonavalent
    • 3.3.3: Bivalent
  • 3.4: Global Human Papillomavirus (HPV) Vaccine Market by Distribution Channel
    • 3.4.1: Hospital & Retail Pharmacies
    • 3.4.2: Government Suppliers
    • 3.4.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Human Papillomavirus (HPV) Vaccine Market by Region
  • 4.2: North American Human Papillomavirus (HPV) Vaccine Market
    • 4.2.2: North American Human Papillomavirus (HPV) Vaccine Market by Distribution Channel: Hospital & Retail Pharmacies, Government Suppliers, and Others
  • 4.3: European Human Papillomavirus (HPV) Vaccine Market
    • 4.3.1: European Human Papillomavirus (HPV) Vaccine Market by Type: Tetravalent, Nonavalent, and Bivalent
    • 4.3.2: European Human Papillomavirus (HPV) Vaccine Market by Distribution Channel: Hospital & Retail Pharmacies, Government Suppliers, and Others
  • 4.4: APAC Human Papillomavirus (HPV) Vaccine Market
    • 4.4.1: APAC Human Papillomavirus (HPV) Vaccine Market by Type: Tetravalent, Nonavalent, and Bivalent
    • 4.4.2: APAC Human Papillomavirus (HPV) Vaccine Market by Distribution Channel: Hospital & Retail Pharmacies, Government Suppliers, and Others
  • 4.5: ROW Human Papillomavirus (HPV) Vaccine Market
    • 4.5.1: ROW Human Papillomavirus (HPV) Vaccine Market by Type: Tetravalent, Nonavalent, and Bivalent
    • 4.5.2: ROW Human Papillomavirus (HPV) Vaccine Market by Distribution Channel: Hospital & Retail Pharmacies, Government Suppliers, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Human Papillomavirus (HPV) Vaccine Market by Type
    • 6.1.2: Growth Opportunities for the Global Human Papillomavirus (HPV) Vaccine Market by Distribution Channel
    • 6.1.3: Growth Opportunities for the Global Human Papillomavirus (HPV) Vaccine Market by Region
  • 6.2: Emerging Trends in the Global Human Papillomavirus (HPV) Vaccine Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Human Papillomavirus (HPV) Vaccine Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Human Papillomavirus (HPV) Vaccine Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Johnson & Johnson
  • 7.2: Xenetic Biosciences
  • 7.3: AstraZeneca
  • 7.4: Merck
  • 7.5: Serum Institute of India
  • 7.6: Inovio Pharmaceuticals
  • 7.7: Bharat Biotech
  • 7.8: Sanofi
  • 7.9: GlaxoSmithKline
  • 7.10: Novartis
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!